Atossa Therapeutics Inc.

News & Events

Press Releases

In The Media

1. Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio

   GlobeNewswire APR 30, 2025 8:45 AM EDT
   SEATTLE, April 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Ato...
   READ ARTICLE

2. Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025

   GlobeNewswire APR 29, 2025 8:45 AM EDT
   SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Ato...
   READ ARTICLE

3. Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio

   GlobeNewswire APR 22, 2025 8:45 AM EDT
   SEATTLE, April 22, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Ato...
   READ ARTICLE

4. Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer

   PR Newswire APR 10, 2025 8:00 AM EDT
   Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies f...
   READ ARTICLE

5. Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

   GlobeNewswire MAR 25, 2025 8:00 AM EDT
   Ended 2024 with $71.1 million of cash and cash equivalents and no debt Conference Call an...
   READ ARTICLE

6. Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

   GlobeNewswire MAR 20, 2025 9:13 AM EDT
   SEATTLE, March 20, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Ato...
   READ ARTICLE

7. Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications

   GlobeNewswire MAR 11, 2025 8:15 AM EDT
   SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (&#x...
   READ ARTICLE

8. Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care

   GlobeNewswire FEB 5, 2025 8:00 AM EST
   SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“...
   READ ARTICLE

9. Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591

   GlobeNewswire JAN 30, 2025 8:17 AM EST
   SEATTLE, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“...
   READ ARTICLE

10. Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

    GlobeNewswire JAN 23, 2025 8:15 AM EST
    SEATTLE, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“...
    READ ARTICLE